By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AnaptysBio, Inc. 

10835 Road to the Cure
Suite 100
San Diego  California  92121  U.S.A.
Phone: 858-362-6295 Fax: 858-362-6296




Company News
AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 4/16/2015 6:29:05 AM
AnaptysBio Recruits Ex-Pfizer (PFE) R&D Star to Lead Translational Biology 4/7/2015 5:32:28 AM
Tesaro, Inc. (TSRO) And AnaptysBio, Inc. Expand Immuno-Oncology Collaboration To Include Novel Bispecific Antibody Candidate 12/2/2014 11:51:12 AM
AnaptysBio, Inc. Appoints Dr. Marco Londei To Newly Created Chief Development Officer Position Clinical Immunologist To Lead Anaptysbio's Pipeline Advancement 10/20/2014 9:00:14 AM
Momenta Pharmaceuticals, Inc. (MNTA) Exercises Option To Acquire Novel Antibodies From AnaptysBio, Inc. 9/8/2014 7:01:10 AM
AnaptysBio, Inc. Announces Issuance Of United States Patent Covering Proprietary Antibody Humanization Technology 4/3/2014 9:32:54 AM
Tesaro, Inc. (TSRO), AnaptysBio, Inc. Strike Immuno-Oncology Pact Worth $125 Million 3/13/2014 7:02:32 AM
AnaptysBio, Inc. Announces Development Of Novel Anti-IL33 Therapeutic Antibody 1/10/2014 10:37:15 AM
AnaptysBio, Inc. Announces Antibody Development Agreement With Momenta Pharmaceuticals, Inc. (MNTA) 12/17/2013 10:44:30 AM
AnaptysBio, Inc. Receives Allowance of US Patent Covering Proprietary ABELmAb™ Libraries 10/17/2013 9:54:32 AM